Else Nutrition Holdings Inc.
BABY.TO
Toronto Stock Exchange0.02
CAD
+0.00
- -
Else Nutrition Holdings Inc.
BABY.TO
(Toronto Stock Exchange)
Recent
price
0.02
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Else Nutrition Holdings Inc. engages in the development, manufacturing, and sale of whole-food, plant-based nutrition products primarily targeting infants, toddlers, children, and adults. The company offers a comprehensive product portfolio including plant-based baby formula products formulated as non-dairy and non-soy alternatives; toddler and children’s nutritional products; baby snacks; complementary food products; baby feeding accessories such as sterile and non-sterile feeding bottles and disposable nipples; and nutritional drinks for toddlers. Its flagship formulas are composed of whole foods including almonds, buckwheat, and tapioca, supplemented with essential vitamins and minerals, catering to customers seeking clean-label, allergen-conscious, and sustainable nutrition alternatives. Else Nutrition operates principally in North America and Israel, with headquarters in Tel Aviv, Israel, and serves both retail and hospital markets. Founded in 2017, Else Nutrition is recognized as a pioneer in plant-based childhood nutrition with an emphasis on clean ingredients and allergen-friendly products. The company has recently undergone significant operational improvements including gross margin expansion and substantial cost reductions, positioning it on a sustainable growth trajectory toward profitability. In 2025, Else Nutrition secured a five-year renewal contract with Israel's largest health fund for its baby feeding accessories line, ensuring continued nationwide supply to hospitals and maternity wards and preserving approximately 7% of its 2024 revenue. This renewal solidifies its leadership in hospital-grade infant feeding solutions. Additionally, Else announced a pivotal FDA funding package in the U.S. intended to streamline regulatory processes that are expected to facilitate market readiness for its innovative plant-based infant formula. Else Nutrition has also recently raised gross proceeds through convertible security funding agreements with investors, enhancing its capital structure to support production scale-up, supply chain improvements, and accelerated market expansion. The company continues to focus on resolving supply challenges, growing its retail and online presence, and advancing clinical development phases for its plant-based infant formula. Strategic partnerships and collaborations for commercial, research, and manufacturing initiatives are ongoing, underscoring Else’s commitment to innovation and global market penetration in clean, plant-based nutrition.
Else Nutrition Reports Fiscal Year 2025 Financial Results and Highlights Operational Progress, Strengthened Financial Foundation, and Clear Path Toward Profitability
Else Nutrition CEO to Present at Investor Summit Virtual on December 9, 2025